Trifaroten

Structural formula
General
Non-proprietary name	Trifaroten
other names	4 '- (2-Hydroxyethoxy) -3 "- (2-methyl-2-propanyl) -4" - (1-pyrrolidinyl) -1,1': 3 ', 1 "-terphenyl-4-carboxylic acid ( IUPAC ) 3 "- tert -Butyl-4 '- (2-hydroxyethoxy) -4" - (pyrrolidin-1-yl) [1', 1 ': 3', 3 "-terphenyl] -4-carboxylic acid (WHO )
Molecular formula	C 29 H 33 NO 4
External identifiers / databases
CAS number 895542-09-3 EC number 842-317-4 ECHA InfoCard 100.278.901 PubChem 11518241 ChemSpider 9693029 DrugBank DB12808 Wikidata Q27236856
Drug information
ATC code	D10 AD06
properties
Molar mass	459.6 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Trifaroten is a fourth generation retinoid and was approved in the United States in October 2019 under the name Aklief for the local treatment of acne vulgaris .

application areas

Trifaroten is indicated for the treatment of acne in patients aged 9 years and over.

Working principle

Trifaroten is an agonist of the retinoic acid receptors, with particular activity on the γ subtype. Stimulation of these receptors leads to the modulation of target genes that are associated with various epidermal processes, including cell differentiation and the mediation of inflammation. The exact process by which trifaroten relieves acne is unknown.

Individual evidence

1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
2. ^ ^{A b} Lesley J Scott: Trifarotene: First Approval. In: Drugs. 2019, doi : 10.1007 / s40265-019-01218-6 . PMID 31713811 .
3. ^ Novel Drug Approvals for 2019 . FDA .
4. ↑ ^{a b} AKLIEF- trifarotene cream, labeling (PDF) . Food and Drug Administration , October 2019.